Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Humana is the 'Biggest Winner' From CMS' Medicare Advantage Star Ratings Impact on 2028 Reimbursements, Oppenheimer Says

Humana is the 'Biggest Winner' From CMS' Medicare Advantage Star Ratings Impact on 2028 Reimbursements, Oppenheimer Says

MT newswireMT newswire2026/10/09 16:46

12:46 PM EDT, 10/09/2026 (MT Newswires) -- Humana (HUM) is the "overwhelming" winner from the Centers for Medicare & Medicaid Services' Medicare Advantage Star Ratings impact on 2028 reimbursements, Oppenheimer said in a Thursday research report. CMS released Star Ratings affecting 2028 reimbursement, with 4+ Star Rating membership exposure at 71% compared with 64% a year earlier, analysts wrote. The brokerage estimated that with 95% of Humana members in 4+ Star plans, the difference will account for over $3.6 billion in revenue for the company, resulting in around $20 in EPS if not passed through to bids, according to the note. Humana's membership-weighted average Star Rating grew from 53% to 95%, driven by a rebound in the national contract, according to Oppenheimer. The brokerage said it reiterated its outperform rating on the stock and increased its price target to $475 per share from $405. Price: 434.65, Change: +47.53, Percent Change: +12.28

12:46 PM EDT, 10/09/2026 (MT Newswires) -- Humana (HUM) is the "overwhelming" winner from the Centers for Medicare & Medicaid Services' Medicare Advantage Star Ratings impact on 2028 reimbursements, Oppenheimer said in a Thursday research report. CMS released Star Ratings affecting 2028 reimbursement, with 4+ Star Rating membership exposure at 71% compared with 64% a year earlier, analysts wrote. The brokerage estimated that with 95% of Humana members in 4+ Star plans, the difference will account for over $3.6 billion in revenue for the company, resulting in around $20 in EPS if not passed through to bids, according to the note. Humana's membership-weighted average Star Rating grew from 53% to 95%, driven by a rebound in the national contract, according to Oppenheimer. The brokerage said it reiterated its outperform rating on the stock and increased its price target to $475 per share from $405. Price: 434.65, Change: +47.53, Percent Change: +12.28
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Former BioNTech executive leads Bambusa Therapeutics (BBTX.US) in sprint to Nasdaq, "boosting" eczema drug trials

Bambusa Therapeutics Inc. has filed for an initial public offering, planning to raise funds for clinical trials of treatments for eczema and other inflammatory diseases.

智通财经•2026/10/10 06:21